DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of Combigan® Ophthalmic Solution in Korea

Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma, Open-Angle; Ocular Hypertension

Intervention: brimonidine tartrate/timolol maleate Ophthalmic Solution (Drug)

Phase: N/A

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan

Summary

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan« (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice.

Clinical Details

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Percentage of Participants Reporting Adverse Events

Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with Open Angle Glaucoma or Ocular Hypertension treated with Combigan®

Ophthalmic Solution as standard of care in clinical practice. Exclusion Criteria:

- None.

Locations and Contacts

Seoul, Korea, Republic of
Additional Information

Starting date: January 2009
Last updated: February 25, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017